Zymeworks (ZYME) Removes its CFO

On March 31, 2024, Zymeworks (NASDAQ: ZYME) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.

In connection with Dr. Astle’s removal, effective March 31, 2024, the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer. In connection with this appointment, Mr. Galbraith will continue in his roles as Chair of the Board, President and Chief Executive Officer and assume the duties of the Company’s principal financial officer and principal accounting officer, until his successor is appointed or until his earlier resignation or removal. The Company has initiated a search for a new Chief Financial Officer.

You May Also Be Interested In

• Circle board member resigns after nearly 13 years of service
• Ticketplus files for IPO with shares priced between $13-$15
• Summit Hotel Properties CFO to depart June 15 for personal reasons